参附注射液改善干扰素所致骨髓抑制临床观察  

Shenfu Zhusheye for interferon-alpha-related myelosuppression in chronic hepatitis B patients

作　　者：王群[1] 孙学强[1] 张晨光[1] 

机构地区：[1]蚌埠医学院第二附属医院感染科,安徽蚌埠233040

出　　处：《蚌埠医学院学报》2010年第7期671-673,共3页Journal of Bengbu Medical College

摘　　要：目的:观察参附注射液对使用干扰素治疗慢性乙型病毒性肝炎过程中发生白细胞、中性粒细胞及血小板减少副作用的预防效果。方法:选择使用α1b-干扰素1周后白细胞、中性粒细胞、血小板减少的慢性乙型病毒性肝炎患者68例,随机分为治疗组和对照组,治疗组34例采用参附注射液治疗,对照组34例采用利血生、鲨甘醇治疗。每周1次静脉取血检测白细胞、中性粒细胞、血小板。结果:参附注射液治疗后白细胞、中性粒细胞均恢复至治疗前水平(P>0.05)。乏力、心慌、纳差、失眠等症状明显改善(P<0.01)。结论:参附注射液对改善因使用干扰素所致骨髓抑制具有较好的临床效果。Objective：To investigate the role of Shenfu Zhusheye in preventing the side effects of interferon-alpha on the white blood cell,red blood cell and blood platelet in chronic hepatitis B patients.Methods：A total of 68 chronic hepatitis B patients with interferon-alpha-related myelosuppression were randomly divided into study group and control group.The control group（34 cases） received combination therapy of leucogen and batilol tablets.The study group（34 cases） received Shenfu Zhusheye intravenous injection.The white blood cell count,neutrophil count and the blood platelet count were measured weekly in both groups.Results：The levels of the plasma blood cell count and neutrophil count in the study group were significantly lower than those in control group（P0.05）.The scores of debility and agrypnia in the study group were lower than those in the control group（P0.01）.Conclusions：Shenfu Zhusheye therapy is effective in preventing interferon-alpha-related myelosuppression in chronic hepatitis B patients.

关 键 词：乙型肝炎 参附注射液 干扰素 骨髓抑制 

分 类 号：R512.62[医药卫生—内科学]